Abstracts tagged "Randomized Trial"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Eric F. Morand¹, Cristina Arriens², Marilyn Pike³, Joan Merrill⁴, Victoria Werth⁵, Zahi Touma⁶, Razvan C. Ionitescu⁷, Masato Okada⁸, Ilias Kouris⁹, Yogita Kolekar¹⁰, Junyu Nie¹⁰, Venkat Renukuntla¹⁰, Thomas Wegman¹⁰ and Ronald van Vollenhoven¹¹, ¹Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Rheumatology, MedPharm Consulting, Inc, Bethesda, ⁴Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, ⁵University of Pennsylvania, Merion Station, Pennsylvania, ⁶University of Toronto, Toronto, Ontario, Canada, ⁷Medart Cliniq, Department of Rheumatology, Râmnicu Vâlcea, Romania, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Eli Lilly and Company Global, Basingstoke, United Kingdom, ¹⁰Bristol Myers Squibb, Princeton, ¹¹Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB20 • ACR Convergence 2025
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Désirée van der Heijde¹, Philip Mease², Carle Paul³, Frank Behrens⁴, Laure Gossec⁵, Yuko Kaneko⁶, Lihi Eder⁷, Laura Coates⁸, Andrew Pink⁹, Weiguo Wan¹⁰, Enrique Soriano¹¹, Piotr Leszczyński¹², Jose Scher¹³, Atul Deodhar¹⁴, Chahin Pachai¹⁵, Janice Li¹⁶, Xue Fan¹⁶, Sahar Rabbat¹⁶, Caroline Sardinas¹⁷, Michael Plewinski¹⁸, John Vaile¹⁹ and Joseph Merola²⁰, ¹Leiden University Medical Center, Meerssen, Netherlands, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ³Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, France, ⁴Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁵Sorbonne Université, AP-HP & EULAR, Paris, France, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁷University of Toronto, Toronto, Ontario, Canada, ⁸University of Oxford, Oxford, United Kingdom, ⁹St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom, ¹⁰Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Department of Internal Medicine and Metabolic Disorders, Poznań University of Medical Sciences, Poznań, Poland, ¹³New York University School of Medicine, New York, New York, ¹⁴Oregon Health & Science University, Portland, Oregon, ¹⁵Bristol Myers Squibb, Princeton, New Jersey, ¹⁶Bristol Myers Squibb, Princeton, ¹⁷Bristol Myers Squibb, garwood, New Jersey, ¹⁸Bristol Myers Squibb, Green Brook Township, New Jersey, ¹⁹Bristol Myers Squibb, Warren, New Jersey, ²⁰UT Southwestern Medical Center, Dallas, Texas
Background/Purpose: Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor being investigated in active PsA in the global, randomized, double-blind, placebo (PBO)-controlled, phase 3…
Abstract Number: 2357 • ACR Convergence 2025
Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Lihi Eder¹, Iain McInnes², Christopher Ritchlin³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Laura Coates⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Matthew R. Thomas⁹, Eva Cullen⁹, Kristian Reich¹⁰, Joseph F Merola¹¹ and Philip J. Mease¹², ¹University of Toronto, Toronto, ON, Canada, ²University of Glasgow, Glasgow, United Kingdom, ³University of Rochester Medical Center, Canandaigua, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of California, San Diego, School of Medicine, San Diego, CA, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 0498 • ACR Convergence 2025
Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
Naveen Reddy¹, Narendra Maharaj¹, Pramod Kumar Reddy¹, Mansi Dhananjaya Jakhade¹, Maria Velinova² and Vendel Kemény³, ¹Biologics, Dr. Reddy’s Laboratories Ltd., Hyderabad, India, Hyderabad, India, ²ICON – Early Development Services Van Swietenlaan ⁶ ⁹⁷²⁸ NZ, Groningen, Netherlands, Groningen, Netherlands, ³ICON Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely Rottenbiller utca ¹³ ¹⁰⁷⁷, Budapest, Hungary, Budapest, Hungary
Background/Purpose: Dr. Reddy’s-abatacept (DRL_AB) is being developed as a biosimilar to the reference product (RP) (RP-US licensed Orencia®) and the reference medicinal product (RMP) (RMP-EU…
Abstract Number: 2353 • ACR Convergence 2025
Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Jian Xu, Yifan Yang, Shuang Liu, Ru Bai, Shu Li, Guofang Zhang, Xiangyu Wang, Xinyu Xu, Mai Zheng and Daying Feng, The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, resulting in significant pain, stiffness, and functional impairment.…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 0645 • ACR Convergence 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Eric Morand¹, Lucy Carter², Maria Dall'Era³, Michelle Petri⁴, Ed Vital⁵, Teri Jimenez⁶, Janine Gaiha-Rohrbach⁷, Bernard Lauwerys⁸, Annette Nelde⁹, Christian Stach¹⁰ and Ronald van Vollenhoven¹¹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, University of California, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶UCB, Raleigh, NC, ⁷Biogen, Cambridge, MA, ⁸Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁹Biogen, Baar, Switzerland, ¹⁰UCB, Monheim am Rhein, Germany, ¹¹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 0477 • ACR Convergence 2025
At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
Alexandre GARMENDIA¹, Valerie Devauchelle², Grégoire CORMIER³, LE GOFF Benoit⁴, Aleth Perdriger⁵, Saloua Mammou⁶, Emannuel Hoppe⁷, Emmanuelle Dernis⁸, Jose Le Noach⁹, Carine Salliot¹⁰, florent garrigues¹, Raphael Auffret¹, Ichem Mohtarif¹¹, Mateusz Chodorowsky¹¹, Thierry MARHADOUR¹², Divi Cornec¹³, Dewi Guellec¹, Emmanuelle Courtois Communier¹, Alain SARAUX¹⁴ and sandrine jousse¹², ¹CHU de BREST, Brest, Bretagne, France, ²UBO, Brest, France, ³Centre Hospitalier département de Vendée, La Roche Sur Yon, France, ⁴CHU Nantes, Nantes, France, ⁵Rennes University, Rennes, France, ⁶CHU TOURS, TOURS, France, ⁷CHU ANGERS, Angers, France, ⁸Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁹Centre Hospitalier de Lorient, Lorient, France, ¹⁰CHR orleans, Orleans, France, ¹¹CHU de Brest, Brest, France, ¹²LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ¹³Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR¹²²⁷: LBAI, Brest, France, Brest, France, ¹⁴CHU Brest, Brest, France
Background/Purpose: Previous studies, including TASER and ARTIC (1,2), failed to demonstrate a significant benefit of ultrasound (US) compared to clinical evaluation in achieving clinical remission…
Abstract Number: 2339 • ACR Convergence 2025
Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Alen Zabotti¹, Joseph F Merola², Ulrich Mrowietz³, Philip J. Mease⁴, Laure Gossec⁵, mitsumasa kishimoto⁶, Michele Brunori⁷, Lichen Teng⁸, Dafna D. Gladman⁹ and Laura Coates¹⁰, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁵Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ⁶Kyorin University School of Medicine, Tokyo, Japan, ⁷Amgen Inc, Zurich, Switzerland, ⁸Amgen Inc., Thousand Oaks, ⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Data on disease progression and joint involvement patterns in early oligoarticular (oligo) PsA are sparse. In the FOREMOST study (NCT03747939), apremilast (APR) decreased the…
Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Philip J. Mease¹, Laure Gossec², Atul Deodhar³, Xenofon Baraliakos⁴, Frank Behrens⁵, Joseph F Merola⁶, Lihi Eder⁷, Ana-Maria Orbai⁸, Andreas Ramming⁹, Iain McInnes¹⁰, Alexis Ogdie¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁶Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
Abstract Number: 0640 • ACR Convergence 2025
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Vibeke Strand¹, Zahi Touma², Anca Askanase³, Christopher Saffore⁴, Denise Kruzikas⁵, Karim Masri⁵, Siran Fang⁵, Yi Peng⁶, Patti Katz⁷ and Marta Mosca⁸, ¹Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ²University of Toronto, Toronto, ON, Canada, ³Columbia University Medical Center, New York, NY, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Maple Grove, MN, ⁷UCSF, San Rafael, CA, ⁸University of Pisa, Pisa, Pisa, Italy
Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…

1
2
3
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].